Watchdog lacked key evidence in BioLogics ruling
In its preliminary ruling on May 1, the Financial Supervisory Service concluded that the pharmaceutical company breached accounting rules and passed its findings to the Financial Services Commission, which will make a final decision on the case.
But the documents from the Financial Supervisory Service, which the JoongAng Ilbo obtained, fail to present conclusive evidence of accounting fraud. When asked about the discrepancy, a source at the Financial Supervisory Service said it would provide conclusive evidence to the Securities and Futures Commission.
The Financial Services Commission is scheduled to conduct a review on May 17, and the Securities and Futures Commission expects to look into the case on either May 23 or June 7 to make a final decision. The Securities and Futures Commission is part of the Financial Services Commission.
The flashpoint of the dispute lies in BioLogics’ motivation to shift the status of Samsung Bioepis from subsidiary to affiliate in 2015. In the process, BioLogics changed the accounting standards applied to Bioepis, using market value instead of book value as previously done.
A civic group was the first to raise allegations that the change might have been made to inflate the value of BioLogics ahead of a planned market listing in 2016. The pharmaceutical company had suffered operating losses for four straight years but pulled off net profit of 1.9 trillion won ($1.7 billion) in 2015. Critics believe the upbeat performance was helped by the new accounting standard since the market-price valuation put Bioepis at 4.8 trillion won, lifting the loss to gains.
In its preliminary ruling, the Financial Supervisory Service said the valuation was inflated by 914.9 billion won. Samsung Bioepis refuted the result, saying the change was in line with global accounting rules. The International Financial Reporting Standards, the accounting standard used in Korea and more than 110 countries, allow a company to use a market-value assessment of an affiliate.
“Even before [Bioepis] got approval for its drugs under development, the company was valued at 4.8 trillion won,” said Yoon Ho-yeol, a director at Samsung BioLogics. “The profitability of Bioepis is based on evaluations from global consulting firms like McKinsey, so there is no problem with our accounting.”
Samsung Bioepis began in 2012 as a joint venture between BioLogics and Biogen, a U.S. biotech company. BioLogics invested 280.5 billion won for an 85 percent stake, and Biogen put in 49.5 billion won for a 15 percent stake plus a call option that could increase its stake up to 49.9 percent by the end of June 2018. Currently, BioLogics holds a 94.6 percent stake in Bioepis. Biogen holds the rest.
As for the reason why BioLogics converted Bioepis’ status three years ago, BioLogics called it a pre-emptive measure against the possibility of Biogen exercising a call option to raise its stake in Bioepis.
Now, the decision goes to the Financial Services Commission. Choi Jong-ku, head of the financial regulator, said on Wednesday that BioLogics will have to defend itself against the Financial Supervisory Service during the commission’s review on May 17.
The procedure, called confrontation, rarely takes place between a company and regulator when the agenda item is a high-stakes issue. Each party will have time to make its case and refute the other’s, a departure from a typical session where a corporate party comes in after commissioners have discussed the case among themselves.
Yoon Suk-heun, the new governor of the Financial Supervisory Service, has vowed to strengthen the agency’s watchdog power, a move seen as an attempt to increase its independence from the Financial Services Commission, which has purview over the Financial Supervisory Service.
Choi on Wednesday stressed cooperation over separation between the two agencies to properly carry out financial oversight and reform.
BY KIM DO-NYUN, PARK EUN-JEE [firstname.lastname@example.org]
More in Finance
Dollar's weakness pushes won to 30-month high
Kospi hits another high on chipmaker optimism
Eight companies agree to share credit card data
Loans to self-employed grow at slower pace in third quarter
Credit card payments in Korea rise in October on year